Synapse - Min Yuen Teo

Results (28)

Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma

Journal Article

Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
ESMO Open (2025)

Fulltext@MSK | Save

Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)

Meeting Abstract

Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer

Meeting Abstract

Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes

Meeting Abstract

Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results

Meeting Abstract

Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma

Meeting Abstract

Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB)

Meeting Abstract

Badri, A.; Guercio, B. J.; Ratna, N.; Gavrilov, D.; Metzker, N.; Duzgol, C.; Teo, M. Y.; Regazzi, A. M.; Supplice, L.; Funt, S. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)

Meeting Abstract

Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Natural history and genomic landscape of chemotherapy-resistant muscle-invasive bladder cancer

Journal Article

Lenis, A. T.; Whiting, K.; Ravichandran, V.; Tallman, J. E.; Alam, S. M.; Chu, C. E.; De Jesus Escano, M.; Bochner, E.; Katims, A.; Reisz, P. A.; more...
JCO Precision Oncology (2024)

Fulltext@MSK | Save